End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
179,600.00 KRW | -0.77% |
|
-0.33% | -4.21% |
Feb. 04 | South Korean Shares Rally on US Tariff Delay; Celltrion Shares Rise 1% on FDA Approval for ACTEMRA Biosimilar | MT |
Feb. 03 | Celltrion Secures FDA Approval for AVTOZMA Tocilizumab Biosimilar | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
---|---|---|---|---|
Average | ||||
Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- A068270 Stock
- Consensus Celltrion, Inc.
- Estimates Revisions